Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Thursday

Milestone Pharmaceuticals (NASDAQ:MIST) is projected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

Milestone Pharmaceuticals Stock Up 6.6 %

Shares of Milestone Pharmaceuticals stock opened at $1.93 on Thursday. The firm has a market cap of $102.92 million, a price-to-earnings ratio of -2.38 and a beta of 1.83. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75. The stock has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $1.79.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Friday, February 28th.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.